glp-1 obesity drug news october 9 2025 Agonists Market Report 2025-2033, By Product, Molecule, and Geo Exploring the Side Effects of

Liraglutide has shown significant weight loss compared with placebo with the majority of participants achieving more than 5% total body weight loss during the follow up period and 33% (vs 10%) achieving 10% total body weight loss or greater

Increased Rate of Gluconeogenesis in Type II Diabetes Mellitus

Despite the benefits of weight reduction, there are many challenges in losing weight and maintaining long-term weight loss

That analysis found that the claims are still relatively niche, but that theyre growing significantly

Schuit F, Campbell JE

As demand grows, new research finds covering GLP-1 medications will drive up premiums for employer-provided coverage by as much as 14 percent , even when access is limited to patients with the highest need